An obesity medication from Viking Therapeutics succeeded in a Phase 2 clinical study, the company said Tuesday, helping patients lose up to nearly 15% of their weight over about three months and further fueling the competition in the exploding obesity drug market.
Shares of the San Diego-based company doubled in premarket trading.
The trial tested four different weekly injectable doses of the Viking drug, called VK2735, over 13 weeks, with patients seeing a dose-dependent amount of weight loss over the period. Those on the highest dose — 15 milligrams — lost 14.7% of weight.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect